Now whilst our resident rather distasteful trolls of RCE forums have (rather racistly?) dismissed Indonesian trials as a waste of time, some little less xenophobic investors might appreciate not only the massive incidence of diabetes, as so boldly and kindly pointed out by @Karritree, but a reiteration the pressing national policy focus on diabetes I spoke of (I appreciate more intelligent and genuine RCE investors will be aware) - backed up with fact rather than fiction, as so often populates RCE threads alas:
Rather than the stereotyping assumptions of some of RCE's less generous posters on Indonesia as a backward country, it actually has quite a high percentage of universal health coverage - Indonesian sources point that figure 96% in 2023, but lets go with the more objective WORLD HEALTH ORGANIZATION figures from when it reported on Indonesia's formal policy on diabetes back in 2021:
"The Government of Indonesia has set up several programs for managing patients with chronic conditions under its national health insurance scheme (Jaminan Kesehatan Nasional; JKN) covering 86% of the population (235 million people) in 2021. One of these is PROLANIS (Program Penanggulangan Penyakit Kronis), a programme to improve the management of care for patients with hypertension and/or diabetes at the primary level and to control costs." (my embolden)
Management tardiness and performance questions aside since RCE's 2016 listing, the Indonesian strategy for R327G really does appear to be a rather natural commercial pathway choice, for all the dismissing by RCE's resident three baiting trolls.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)